The FDA said in a letter to the company published on Friday that the data submitted by the company is insufficient proof of clinical benefit for bitopertin.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns